Recently, a fusion-specific antibody (clone E9X9V) that recognizes the junction of the SS18-SSX fusion proteins has been shown to be highly sensitive (95%) and specific (100%) for synovial sarcoma, which shows strong and diffuse nuclear positivity (Figure 3). This evidence concerns the gene SS18 and synovial sarcoma.